

WEST Search History

DATE: Sunday, February 08, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=USPT; PLUR=NO; OP=OR</i>		
<input type="checkbox"/>	L35	L34 and (mmp)	1
<input type="checkbox"/>	L34	l28 and (lysozyme)	27
<input type="checkbox"/>	L33	L28 and (mmp adj 1)	2
<input type="checkbox"/>	L32	L28 and (mmp adj 12)	0
<input type="checkbox"/>	L31	L28 and (mmp adj 12)	0
<input type="checkbox"/>	L30	L28 and l10	0
<input type="checkbox"/>	L29	L28 and l6	0
<input type="checkbox"/>	L28	L27 and l24	116
<input type="checkbox"/>	L27	l20 and l3	296
<input type="checkbox"/>	L26	l20 and l2	0
<input type="checkbox"/>	L25	l14 and l20	0
<input type="checkbox"/>	L24	l20 and l1	652
<input type="checkbox"/>	L23	L22 l20 and l1	656
<input type="checkbox"/>	L22	L20 and (l11 or l10 or l9 or l7)	4
<input type="checkbox"/>	L21	L20 and (l11 or l10 or l9 or l7 or l1 or l2 or l3)	836
<input type="checkbox"/>	L20	(inflammatory adj bowel adj disease) or ibd	4893
<input type="checkbox"/>	L19	L11 and l10 and l9 and l7	0
<input type="checkbox"/>	L18	L11 and l10	0
<input type="checkbox"/>	L17	L16 and l6	0
<input type="checkbox"/>	L16	l14 and l3	1
<input type="checkbox"/>	L15	L14 and l2	0
<input type="checkbox"/>	L14	l11 and l1	1
<input type="checkbox"/>	L13	L11 and l10	0
<input type="checkbox"/>	L12	L11 and l10 and l9 and l7 and l6	0
<input type="checkbox"/>	L11	(max adj interacting adj protein adj 1) or mxii	9
<input type="checkbox"/>	L10	(down adj regulated adj in adj rhabdosarcoma) or dral	115
<input type="checkbox"/>	L9	calgizzarin	9
<input type="checkbox"/>	L8	calgizzatin	0
<input type="checkbox"/>	L7	dd96	4
<input type="checkbox"/>	L6	dra or (down adj regulated adj adenoma)	913
<input type="checkbox"/>	L5	gos2	16

<input type="checkbox"/>	L4	(phospholipase adj a2 adj group adj iia) or pla2g2a	8
<input type="checkbox"/>	L3	metallothionein	5003
<input type="checkbox"/>	L2	(growth adj hormone adj 2) or gh2	139
<input type="checkbox"/>	L1	(il adj 8) or mdncf	2299

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 11:15:17 ON 08 FEB 2004)

FILE 'MEDLINE, SCISEARCH' ENTERED AT 11:16:02 ON 08 FEB 2004

FILE 'MEDLINE, CAPLUS, SCISEARCH' ENTERED AT 11:16:26 ON 08 FEB 2004

L1	28428 S INFLAMMATORY BOWEL DISEASE
L2	30656 S L1 OR IBD
L3	16 S L2 AND IL8
L4	2823 S IP-10
L5	544 S (GROWTH HORMONE 2) OR GH2
L6	108 S GRO1
L7	32 S GRO2
L8	432 S (NEUTROPHIL LIPOCALIN) OR HNL
L9	23714 S METALLOTHIONEIN
L10	36 S DD96 OR (EPITHELIAL PROTEIN UPREGULATED IN CARCINOMA)
L11	92 S CALGIZZARIN
L12	156 S DRAL OR (DOWN REGULATED IN RHABDOSARCOMA)
L13	12 S MAX INTERACTING PROTEIN 1
L14	0 S L2 AND L13 AND L12 AND L11 AND L10 AND L9
L15	1 S L2 AND L13

FILE 'STNGUIDE' ENTERED AT 11:23:05 ON 08 FEB 2004

FILE 'MEDLINE, SCISEARCH, CAPLUS' ENTERED AT 11:26:31 ON 08 FEB 2004

L16	5 S L2 AND L12
L17	19 S L2 AND L4
L18	0 S L17 AND L9
L19	1 S L17 AND L5
L20	1 S L17 AND IL8
L21	29 S L2 AND IL6
L22	0 S L21 AND L9
L23	2 S L21 AND MMP
L24	49 S L2 AND MICROARRAY#

FILE 'GENBANK' ENTERED AT 11:40:21 ON 08 FEB 2004

L25	2 S Y00787
L26	34 S X54489
L27	2 S M57731
L28	2 S M28130
L29	36 S J03756
L30	1 S S75256
L31	2 S X99133
L32	1 S X85781
L33	3 S X65965
L34	114 S M22430
L35	1 S X51441
L36	1 S J03474
L37	9 S M21119
L38	53 S D00408
L39	46 S D14662

FILE 'CAPLUS' ENTERED AT 11:43:49 ON 08 FEB 2004

L40	0 S L39 AND L38 AND L37 AND L36 AND L35 AND L34
L41	0 S L39 AND L38 AND L37 AND L36 AND L35
L42	0 S L39 AND L38 AND L37 AND L36
L43	0 S L39 AND L38 AND L37
L44	0 S L39 AND L38 AND L37 AND (L36 OR L35 OR L34)
L45	0 S L39 AND L38 AND (L37 OR L36 OR L35 OR L34)
L46	9 S L39
L47	1 S L46 AND L2
L48	0 S L38 AND L2

L49	0 S L37 AND L2
L50	0 S L37 AND L2
L51	0 S L36 AND L2
L52	0 S L35 AND L2
L53	0 S L34 AND L2
L54	0 S L33 AND L2
L55	0 S L25 AND L2
L56	0 S L26 AND L2
L57	0 S L27 AND L2
L58	1 S L28 AND L2
L59	0 S L29 AND L2
L60	0 S L30 AND L2
L61	0 S L31 AND L2
L62	0 S L31 AND L2
L63	0 S L33 AND L2
	E LAWRENCE IAN C/AU
	E FIOCCHI CLAUDIO/AU
L64	6 S E1
L65	50 S E3
L66	0 S L64 AND L65
L67	56 S L64 OR L65
L68	34 S L67 AND L2
L69	1 S L68 AND MICROARRAY#
L70	1 S L69
L71	1 S L68 AND HNL
L72	1 S NGAL AND L68
	E LAWRENCE IAN C/AU
L73	2 S E3
	E CHAKRAVARTI SHUKTI/AU
L74	4 S E3 AND L2

=>

L68 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:521277 CAPLUS
 DN 125:192733
 ED Entered STN: 30 Aug 1996
 TI Interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**
 AU Matsuura, Toshihiro; Kusugami, Kazuo; Morise, Kimitomo; **Fiocchi, Claudio**
 CS 1st Dep. Internal Med., Nagoya Univ. Sch. Med., Nagoya, Japan
 SO Cytokines in Inflammatory Bowel Disease (1996), 41-56. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.
 CODEN: 63GUAH
 DT Conference; General Review
 LA English
 CC 15-0 (Immunochemistry)
 AB A review, with 98 refs. The authors discuss interleukin-2 activity by intestinal mucosal mononuclear cells in **inflammatory bowel disease (IBD)**, soluble interleukin-2 receptor production by lamina propria mononuclear cells, lymphokine-activated killer cell activity in **IBD**, and levels of IL-2 and IL-2R mRNA in **IBD**.
 ST review interleukin 2 **inflammatory bowel disease**
 IT Intestine, disease
 (inflammatory, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)
 IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (interleukin 2, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)
 IT Lymphokine and cytokine receptors
 Receptors
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)
 (interleukin 2, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)

L68 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:521279 CAPLUS
 DN 125:192735
 ED Entered STN: 30 Aug 1996
 TI Interleukin-6 in **inflammatory bowel disease**
 AU Kusugami, Kazuo; Morise, Kimitomo; Shinoda, Masataka; Haruta, Jun-ichi; Tanimoto, Mitsune
 CS 1st Dep. Internal Med., Nagoya Univ. Sch. Med., Nagoya, Japan
 SO Cytokines in Inflammatory Bowel Disease (1996), 69-83. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.
 CODEN: 63GUAH
 DT Conference; General Review
 LA English
 CC 15-0 (Immunochemistry)
 AB A review, with 89 refs. Based on the multitude of biol. functions of IL-6 on essentially all tissues and cells in the body, this cytokine has also attracted much attention in the pathogenesis of **inflammatory bowel disease (IBD)** under the assumption that dysregulation of IL-6 activity may be associated with immune abnormalities in patients with ulcerative colitis and Crohn's disease. This paper discusses IL-6 in **IBD**, keeping in mind that the investigation of

IL-6 in **IBD** patients to clarify its involvement in the pathogenesis and perpetuation of **IBD** is still in progress.

ST review interleukin 6 **inflammatory bowel disease**

IT Intestine, disease
(inflammatory, interleukin-6 in **inflammatory bowel disease**)

IT Lymphokines and Cytokines
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(interleukin 6, interleukin-6 in **inflammatory bowel disease**)

L68 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:521281 CAPLUS
DN 125:192737
ED Entered STN: 30 Aug 1996
TI Chemotactic cytokines (chemokines) in **inflammatory bowel disease**

AU MacDermott, Richard P.; Izutani, Ryo; Ohno, Yasuhiro; Reinecker, Hans-Christian

CS Gastroenterology Section, Lahey Clinic, Burlington, MA, USA

SO Cytokines in Inflammatory Bowel Disease (1996), 101-118. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.
CODEN: 63GUAH

DT Conference; General Review

LA English

CC 15-0 (Immunochemistry)

AB A review with 102 refs. The presence of large nos. of granulocytes and macrophages in the bowel wall is a common feature in **inflammatory bowel disease (IBD)**. Granulocytes and macrophages are thought to contribute to the immunopathogenesis of **IBD**. The constant flux of granulocytes and macrophages indicates the likely presence of potent chemotactic agents in inflamed intestinal mucosa. The regulation of granulocyte and macrophage movement into inflamed mucosal and submucosal tissue may also be mediated by chemokines, which are potent mediators of granulocyte and macrophage migration and activation. Two of the chemokines, interleukin-8 and monocyte chemotactic and activating factor (MCAF) are likely to have important roles in mediating chronic intestinal inflammation in diseases such as **IBD**

ST review chemokine **inflammatory bowel disease**

IT Lymphokines and Cytokines
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(chemokines, chemotactic cytokines (chemokines) in **inflammatory bowel disease**)

IT Intestine, disease
(inflammatory, chemotactic cytokines (chemokines) in **inflammatory bowel disease**)

L68 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:521282 CAPLUS
DN 125:192738
ED Entered STN: 30 Aug 1996
TI The colony-stimulating factors in **inflammatory bowel disease**

AU Doe, William F.; Grimm, Michael C.

CS John Curtin Sch. Clinical Res., Australian natl. Univ., Canberra City, Australia

SO Cytokines in Inflammatory Bowel Disease (1996), 119-136. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.
CODEN: 63GUAH

DT Conference; General Review

LA English
 CC 15-0 (Immunochemistry)
 AB A review, with 65 refs. The authors discuss the biol. activities of each of the colony-stimulating factors (CSFs), their potential roles and synergies in immune and inflammatory responses and the potential effects of these functions on the regulation and mediation of mucosal inflammation in **inflammatory bowel disease (IBD)**).
 ST review colony stimulating factor bowel disease
 IT Intestine, disease
 (inflammatory, colony-stimulating factors in **inflammatory bowel disease**)
 IT 62683-29-8, Colony-stimulating factor
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (colony-stimulating factors in **inflammatory bowel disease**)

L68 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:521283 CAPLUS
 DN 125:192063
 ED Entered STN: 30 Aug 1996
 TI Peptide growth factors in **inflammatory bowel disease**
 AU Dignass, Axel U.; Podolsky, Daniel K.
 CS Dep. Med., Univ. Essen, Essen, Germany
 SO Cytokines in Inflammatory Bowel Disease (1996), 137-155. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.
 CODEN: 63GUAH
 DT Conference; General Review
 LA English
 CC 14-0 (Mammalian Pathological Biochemistry)
 AB A review, with 76 refs., of general properties of prototypic peptide growth factors which are likely to be important in **inflammatory bowel disease** including EGF, TGF- α , TGF- β , IGF, FGF, HGF, CSF, and trefoil factors.
 ST review growth factor **inflammatory bowel disease**
 IT Animal growth regulators
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (peptide growth factors in **inflammatory bowel disease**)
 IT Intestine, disease
 (inflammatory, peptide growth factors in **inflammatory bowel disease**)

L68 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:547943 CAPLUS
 DN 125:219585
 ED Entered STN: 13 Sep 1996
 TI Cytokines in **Inflammatory Bowel Disease**.
 AU **Fiocchi, Claudio**; Editor
 CS USA
 SO (1996) Publisher: (Landes, Austin, Tex.), 265 pp.
 DT Book
 LA English
 CC 15-8 (Immunochemistry)
 Section cross-reference(s): 14
 AB Unavailable
 ST book cytokine **inflammatory bowel disease**
 IT Lymphokines and Cytokines
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(cytokines in **inflammatory bowel disease**)

IT Intestine, disease
(inflammatory, cytokines in **inflammatory bowel disease**)

L68 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:521276 CAPLUS

DN 125:192732

ED Entered STN: 30 Aug 1996

TI Interleukin-1 and interleukin-1 receptor antagonist in
inflammatory bowel disease

AU Kam, Lori; Cominelli, Fabio

CS Div. Gastrointestinal Liver Diseases, Univ. Southern California Sch. Med.,
Los Angeles, CA, USA

SO Cytokines in Inflammatory Bowel Disease (1996), 27-39. Editor(s):
Fiocchi, Claudio. Publisher: Landes, Austin, Tex.
CODEN: 63GUAH

DT Conference; General Review

LA English

CC 15-0 (Immunochemistry)

AB A review, with 36 refs. Immune cells and their cytokines are likely to
play an important role in the initiation and perpetuation of the chronic
inflammation associated with ulcerative colitis and Crohn's disease.
Activated mononuclear cells produce interleukin-1 (IL-1), a
pro-inflammatory cytokine with multiple biol. properties that may be
responsible for the initiation and amplification of the inflammatory
response. Macrophage activation has been hypothesized to be an early
event in the pathogenesis of intestinal bowel disease (**IBD**).
This suggests that IL-1 is also involved in the early events of the
inflammatory cascade. This paper reviews the role of IL-1 and IL-1ra in
IBD, and discusses new strategies for treatment of **IBD**
based on the modulation of IL-1 activity.

ST review interleukin 1 **inflammatory bowel disease**

IT Intestine, disease
(inflammatory, interleukin-1 and interleukin-1 receptor antagonist in
inflammatory bowel disease)

IT Lymphokines and Cytokines
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(interleukin 1, interleukin-1 and interleukin-1 receptor antagonist in
inflammatory bowel disease)

IT Lymphokines and Cytokines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(interleukin 1 receptor antagonist, interleukin-1 and interleukin-1
receptor antagonist in **inflammatory bowel disease**)